Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
PWNA’s Reservation Animal Rescue Program Receives $10,000 from NAVC Gives
-
Cenovus announces third-quarter 2026 results
-
Ridgepost Capital Reports Third Quarter 2026 Financial Results
-
Stella-Jones Announces Normal Course Issuer Bid
-
SFL - Third Quarter 2026 Results
-
Pure DC Unveils ~$2Billion Financing Framework to Scale Its Differentiated Pan-European & Middle East Cloud & AI Infrastructure Platform
-
Pure DC Unveils ~$2Billion Financing Framework to Scale Its Differentiated Pan-European & Middle East Cloud & AI Infrastructure Platform
-
Form 8.3 - Gamma Communications Plc
-
B2BROKER Expands B2TRADER AI Strategy With MCP Trading Agents and In-Terminal Chat
-
West Red Lake Gold Announces Integrated PFS Delivering C$764 Million Post-Tax NPV and Annual Gold Production of 100,000 Ounces Once Rowan Enters Production
-
Man Group PLC : Form 8.3 - Gamma Communications Plc
-
Man Group PLC : Form 8.3 - RHI Magnesita N.V.
-
Man Group PLC : Form 8.3 - Sthree plc
-
Man Group PLC : Form 8.3 - Vesuvius Plc
-
Scale Factory Achieves AWS Premier Tier Services Partner Status and Named as a “Rising Star” in the ISG Provider Lens® AWS Ecosystem Partners 2026 Report for the UK
-
Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc
-
Transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Inflation and Borrowing Costs Impacted October GTA Real Estate Market
-
KE Holdings Inc. to Report Third Quarter 2026 Financial Results on November 16, 2026 Eastern Time
-
JD.com to Report Third Quarter 2026 Financial Results on November 17, 2026
-
Compliance and risk teams are handling regulatory change faster, but fewer believe their approach is effective, CUBE survey finds
-
Dimensional Fund Advisors Ltd. : Form 8.3 - TATE & LYLE PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - PROLOGIS INC - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - Irish Residential Properties REIT plc - Ordinary Shares
-
Dimensional Fund Advisors Ltd. : Form 8.3 - DCC Energy PLC - Ordinary Shares
-
ADIGHERIN SRL Reports Nearly Double the Net Profit in 2025 as Toro Nero Plans European Expansion
-
Transaction in Own Shares
-
TRUNNANO Launches Upgraded Nano-Modified Lithium-Based Concrete Curing Agent to Revolutionize Floor Hardening and Sealing
-
Result of the auction of 2.00 per cent DGB 2028 and 2.25 per cent DGB 2035
-
PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts
-
Notice to Annual General Meeting of SkiStar AB
-
Friendly Technologies Announces Service Orchestration Capabilities to Help Providers Grow Revenue Beyond Broadband
-
Form 8.5 (EPT/RI) - Pharos Energy Plc
-
Form 8.5 (EPT/RI) - Kore Potash Plc
-
fomo Reports Approximately 3.2 Million Users as It Builds a Broader Social Finance Platform
-
Festi hf.: Results of share buyback by way of a reverse tender offer
-
Final amounts of mortgage covered bonds series 10F and 10G to be put on auction
-
VEON’s Banglalink Launches Mukto Pay, Expanding Digital Financial Services in Bangladesh
-
VEON’s Banglalink Launches Mukto Pay, Expanding Digital Financial Services in Bangladesh
-
FHS Living Reveals First Speakers for Paris Edition as Hotelisation Reshapes Europe's Real Estate Sector
-
JLT Mobile Computers Nomination Committee 2027
-
“Building Armenia’s Next Phase of Growth”: the first FT Live forum in Armenia, in partnership with Wilco Wealth Management
-
Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 03 11 2026] - (CGWL)
-
Notification of share transactions by Lumen Investments S.à r.l
-
CMS(867.HK/8A8.SG): Ruxolitinib Phosphate Cream Approved in Singapore, Filling Gap in Vitiligo Treatment
-
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
-
Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026
-
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
-
Boehringer Ingelheim and SBP Group enter partnership to advance next-generation cancer therapies


